At 1 year , the incidence of major adverse cardiac events ( death , nonfatal myocardial infarction , stroke , or repeat target vessel revascularization ) was significantly higher in the titanium group than in the everolimus group ( total , 14.5 % vs 4.4 % ; P = .02 ; noninsulin-dependent subgroup , 9.7 % vs 3.2 % ; P = .14 ; insulin-dependent subgroup , 28.6 % vs 7.1 % ; P = .04 ) .